| abstract |
The invention relates to a novel multivalent vaccine formulation based on polysaccharide-protein conjugates. The formulation is a pentavalent formulation, liquid or lyophilized or liquid-lyo combination type, of polysaccharides of the capsule of serogroups A, C, Y, W and X of Neisseria meningitidis (MenA, C, Y, W, X), each polysaccharide being separately conjugated to a carrier protein, tetanus toxoid (TT), to obtain MenA, C, Y, W, X-TT conjugates, associated with one or more buffers and with or without adjuvant, and than pharmaceutically acceptable components / excipients. |